

Marie Christine BÃ©nÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5539622/publications.pdf>

Version: 2024-02-01

153
papers

5,199
citations

147801
31
h-index

95266
68
g-index

156
all docs

156
docs citations

156
times ranked

6100
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues”Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
3	Letter to the editor with regard to the article entitled “Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes”. Cytometry Part B - Clinical Cytometry, 2022, 102, 76-76.	1.5	0
4	Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation. Hamostaseologie, 2022, 42, 185-192.	1.9	3
5	Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective. Journal of Infection, 2022, 84, 94-118.	3.3	2
6	Interference in platelet count due to microspherocytosis related to extensive burn injury. International Journal of Laboratory Hematology, 2022, 44, 57-58.	1.3	0
7	Safety and antibody response after one and/or two doses of BNT162b2 Anti&SARS&CoV&2 mRNA vaccine in patients treated by CAR T cells therapy. British Journal of Haematology, 2022, 196, 360-362.	2.5	24
8	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Advances, 2022, 6, 1804-1812.	5.2	14
9	Hemophagocytic lymphohistiocytosis, what about hair?. American Journal of Hematology, 2022, 97, 508-509.	4.1	0
10	Interest of a third dose of BNT162b2 anti&SARS&CoV&2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2022, 196, .	2.5	21
11	Humoral response to mRNA anti&COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Advances, 2022, 6, 207-211.	5.2	38
12	Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine, 2022, 63, 1008-1013.	5.0	4
13	Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic <scp>Flow&Self</scp> Organizing Maps algorithm. Cytometry Part B - Clinical Cytometry, 2022, 102, 134-142.	1.5	5
14	Anti&SARS&CoV&2 vaccines in recipient and/or donor before allotransplant. EJHaem, 2022, , .	1.0	4
15	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 279.e1-279.e4.	1.2	10
16	A series of case studies illustrating the role of flow cytometry in the diagnostic work&up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	5
17	Suffering neutrophils& where is the enemy?. International Journal of Laboratory Hematology, 2022, 44, 806-807.	1.3	0
18	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 448.	4.4	24

#	ARTICLE	IF	CITATIONS
19	Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?. <i>Current Oncology Reports</i> , 2022, 24, 1015-1022.	4.0	8
20	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	2.7	35
21	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in <i>KMT2Ar</i> acute leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29683.	1.5	0
22	Effectiveness of a third dose of BNT162b2 antiâ€SARSâ€CoVâ€2 mRNA vaccine over a 6â€month followâ€up period in allogeneic hematopoietic stem cells recipients. <i>Hematological Oncology</i> , 2022, 40, 1097-1099.	1.7	8
23	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	1.4	5
24	Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2022, 57, 1435-1441.	2.4	2
25	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2021, 100, 285-287.	1.8	1
26	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021, 60, 466-474.	1.8	4
27	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	7.2	5
28	Flow cytometry for platelets, EDTA or not EDTA: what is the answer?. <i>Platelets</i> , 2021, 32, 144-145.	2.3	0
29	Therapeutic targets in childhood Bâ€acute lymphoblastic leukemia: what about HER2/neu?. <i>Hematological Oncology</i> , 2021, 39, 270-272.	1.7	1
30	Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckmanâ€Coulter DxH 800 Hematology Analyzer. <i>Cancers</i> , 2021, 13, 389.	3.7	11
31	Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 629.	3.7	23
32	Fortuitous discovery of an NPM1 mutation in a myelodysplastic syndrome. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1258-1259.	1.3	0
33	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. <i>European Journal of Haematology</i> , 2021, 106, 859-867.	2.2	2
34	Unsupervised flow cytometry analysis in hematological malignancies: A new paradigm. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 54-64.	1.3	13
35	Issue Highlightsâ€September 2021. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 537-540.	1.5	0
36	Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia. <i>Annals of Hematology</i> , 2021, 100, 2677-2682.	1.8	5

#	ARTICLE	IF	CITATIONS
37	The Plasmacytoid Dendritic Cell CD123+ Compartment in Acute Leukemia with or without RUNX1 Mutation: High Inter-Patient Variability Disclosed by Immunophenotypic Unsupervised Analysis and Clustering. Hemato, 2021, 2, 572-585.	0.6	2
38	Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2021, 4, e2126344.	5.9	55
39	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1378-1390.	10.7	84
40	Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of caseâ€“control studies including 3,955 cases and 9,948 controls. Scientific Reports, 2021, 11, 2007.	3.3	11
41	Definition of Erythroid Differentiation Subsets in Normal Human Bone Marrow Using FlowSOM Unsupervised Cluster Analysis of Flow Cytometry Data. HemaSphere, 2021, 5, e512.	2.7	7
42	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
43	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3911-3911.	1.4	1
44	Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients. Blood, 2021, 138, 3908-3908.	1.4	0
45	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. Blood, 2021, 138, 3465-3465.	1.4	0
46	Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. Cancers, 2021, 13, 5699.	3.7	6
47	Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy. Blood, 2021, 138, 254-254.	1.4	1
48	Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. Blood, 2021, 138, 4914-4914.	1.4	0
49	CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. Blood, 2021, 138, 243-243.	1.4	18
50	Single Capture High Throughput Sequencing Assay for Combined V(D)J Clonality Analysis and Oncogene Mutations in the Diagnosis of T and B Lymphoid Malignancies. Blood, 2021, 138, 2404-2404.	1.4	0
51	A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft. Blood, 2021, 138, 1812-1812.	1.4	1
52	Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine. Blood, 2021, 138, 2895-2895.	1.4	0
53	Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene, 2020, 39, 1198-1212.	5.9	32
54	Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?. Transfusion Medicine Reviews, 2020, 34, 128-129.	2.0	1

#	ARTICLE	IF	CITATIONS
55	Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche. International Journal of Molecular Sciences, 2020, 21, 8584.	4.1	8
56	Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 3595.	3.7	11
57	Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. Journal of Immunology, 2020, 205, 1441-1448.	0.8	9
58	Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. Cancers, 2020, 12, 1927.	3.7	15
59	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. Blood Advances, 2020, 4, 5322-5335.	5.2	8
60	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. Scientific Reports, 2020, 10, 15399.	3.3	3
61	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. EJHaem, 2020, 1, 318-322.	1.0	2
62	Reactive oxygen species levels differentiate CD34 + human progenitors based on CD38 expression. Cytometry Part B - Clinical Cytometry, 2020, 98, 516-521.	1.5	3
63	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. Annals of Hematology, 2020, 99, 1341-1350.	1.8	7
64	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <sc>LYSA</sc> group. Hematological Oncology, 2020, 38, 446-455.	1.7	5
65	Flow cytometry in the diagnosis of mature B-cell lymphoproliferative disorders. International Journal of Laboratory Hematology, 2020, 42, 113-120.	1.3	11
66	Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints. Cytometry Part B - Clinical Cytometry, 2020, 98, 464-475.	1.5	12
67	Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study. Journal of Thrombosis and Thrombolysis, 2020, 50, 995-1003.	2.1	6
68	Good IgA Bad IgG in SARS-CoV-2 Infection?. Clinical Infectious Diseases, 2020, 71, 897-898.	5.8	23
69	Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group. Blood, 2020, 136, 29-30.	1.4	1
70	Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases. Blood, 2020, 136, 2-3.	1.4	0
71	Unsupervised Flow Cytometry Analysis: Application to Minimal Residual Disease Detection in a Cohort of 40 Acute Myeloblastic Leukemia Patients with Molecular Markers. Blood, 2020, 136, 30-30.	1.4	0
72	Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases. Blood, 2020, 136, 37-38.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?. Hematological Oncology, 2019, 37, 80-84.	1.7	15
74	An Râ€Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 1191-1197.	1.5	28
75	Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia, 2019, 33, 1814-1816.	7.2	10
76	The wonderful story of monoclonal antibodies. International Journal of Laboratory Hematology, 2019, 41, 8-14.	1.3	2
77	Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 183-194.	1.5	33
78	Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta Haematologica, 2019, 141, 232-244.	1.4	57
79	Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood Bâ€Lineage Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 128-133.	1.5	6
80	Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cellâ€Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. Journal of Immunology, 2019, 202, 2141-2152.	0.8	32
81	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	5.2	72
82	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Advances, 2019, 3, 4271-4279.	5.2	19
83	Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning. HemaSphere, 2019, 3, e173.	2.7	21
84	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British Journal of Haematology, 2019, 184, 625-633.	2.5	10
85	Bendamustine plus rituximab in newlyâ€diagnosed Waldenstrâ€m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). British Journal of Haematology, 2019, 186, 146-149.	2.5	51
86	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 906-911.	2.0	6
87	A new case of heterozygous variant of the <i><sc>GP</sc>1<sc>BB</sc></i> gene responsible for macrothrombocytopenia. British Journal of Haematology, 2019, 186, 157-159.	2.5	4
88	Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study <sc>ERHEA</sc>. British Journal of Haematology, 2019, 185, 764-767.	2.5	9
89	Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma. Blood, 2019, 134, 1799-1799.	1.4	2
90	Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group. Blood, 2019, 134, 4112-4112.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3319-3319.	1.4	0
92	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allogeneic Transplant Using Purine Analogue/Busulfan-Based Conditioning Regimen. <i>Blood</i> , 2019, 134, 1985-1985.	1.4	0
93	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. <i>Blood</i> , 2019, 134, 5771-5771.	1.4	0
94	CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5 ⁺ B-cell neoplasms. <i>Hematological Oncology</i> , 2018, 36, 607-609.	1.7	7
95	Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1044-1047.	2.4	6
96	Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018, 103, e143-e146.	3.5	41
97	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	1.4	796
98	A new mutation of ANO6 in two familial cases of Scott syndrome. <i>British Journal of Haematology</i> , 2018, 180, 750-752.	2.5	15
99	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	1.4	121
100	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations. <i>Haematologica</i> , 2018, 103, e13-e16.	3.5	18
101	Panel proposal for the immunophenotypic diagnosis of hematological malignancies. A collaborative consensus from the groupe d'Etude Immunologique des LeucÃ©mies (GEIL). <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 542-547.	1.5	10
102	Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. <i>Hematological Oncology</i> , 2018, 36, 422-428.	1.7	18
103	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	1.6	32
104	A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. <i>British Journal of Haematology</i> , 2018, 183, 736-746.	2.5	15
105	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	3.5	49
106	Evaluation of minimal residual disease in childhood ALL. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 104-108.	1.3	3
107	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Oncotarget</i> , 2018, 9, 11451-11464.	1.8	46
108	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i> , 2018, 9, 33528-33535.	1.8	17

#	ARTICLE	IF	CITATIONS
109	Cytom�trie en flux. , 2018, , 27-39.		0
110	Maladie r�siduelle mol�culaire. , 2018, , 301-306.		0
111	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy � a Study By the Lysa Group. Blood, 2018, 132, 4099-4099.	1.4	0
112	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. Blood, 2018, 132, 2846-2846.	1.4	0
113	Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia. Hematological Oncology, 2017, 35, 237-243.	1.7	4
114	Impact of body�surface area on patients� outcome in younger adults with acute myeloid leukemia. European Journal of Haematology, 2017, 98, 443-449.	2.2	6
115	Research in morphology and flow cytometry is at the heart of hematology. Haematologica, 2017, 102, 421-422.	3.5	2
116	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <sc>JAK</sc> inhibitors era?. European Journal of Haematology, 2017, 99, 60-69.	2.2	5
117	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	3.5	74
118	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 1250-1260.	27.0	313
119	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood, 2017, 130, 1832-1844.	1.4	66
120	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	1.8	153
121	Innovation in hematology: morphology and flow cytometry at the crossroads. Haematologica, 2016, 101, 394-395.	3.5	1
122	<sc>CD</sc>180 expression in <sc>B</sc>�cell lymphomas: A multicenter <sc>GEIL</sc> study. Cytometry Part B - Clinical Cytometry, 2016, 90, 462-466.	1.5	16
123	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. Blood, 2016, 128, 5268-5268.	1.4	5
124	Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells. Blood, 2016, 128, 5866-5866.	1.4	0
125	Comparative Value of the Assessment of Minimal Residual Disease in Peripheral Blood at Days 8 and 15 By Flow Cytometry in Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5270-5270.	1.4	1
126	The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica, 2015, 100, e114-e115.	3.5	7

#	ARTICLE	IF	CITATIONS
127	The routine leukocyte differential flow cytometry <sc>H</sc>emato<sc>F</sc>lowâ„¢ method: A new flagging system for automatic validation. Cytometry Part B - Clinical Cytometry, 2015, 88, 375-384.	1.5	15
128	Leukemia diagnosis: today and tomorrow. European Journal of Haematology, 2015, 95, 365-373.	2.2	21
129	Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome. British Journal of Haematology, 2015, 171, 290-292.	2.5	16
130	Place de la cytométrie en flux dans le diagnostic et le suivi des leucémies aiguës. Revue Francophone Des Laboratoires, 2015, 2015, 35-41.	0.0	0
131	Acute Leukemias of Ambiguous Origin. American Journal of Clinical Pathology, 2015, 144, 361-376.	0.7	46
132	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica, 2015, 100, e128-e131.	3.5	26
133	Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial. Blood, 2015, 126, 3787-3787.	1.4	1
134	First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. Blood, 2015, 126, 4170-4170.	1.4	1
135	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. Blood, 2015, 126, 3218-3218.	1.4	0
136	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. Blood, 2015, 126, 4339-4339.	1.4	0
137	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. Blood, 2015, 126, 1947-1947.	1.4	0
138	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica, 2014, 99, 46-53.	3.5	44
139	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	1.4	281
140	Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. Haematologica, 2014, 99, 951-953.	3.5	0
141	Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. British Journal of Haematology, 2013, 161, 551-555.	2.5	38
142	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	1.3	66
143	Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS â€“ part V â€“ assay performance criteria. Cytometry Part B - Clinical Cytometry, 2013, 84, 315-323.	1.5	153
144	Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEL study. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83, 1066-1072.	1.5	36

#	ARTICLE	IF	CITATIONS
145	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. <i>Blood</i> , 2012, 119, 2943-2948.	1.4	45
146	Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. <i>Blood</i> , 2012, 119, 2474-2477.	1.4	14
147	Acute leukemias of ambiguous lineage. <i>Seminars in Diagnostic Pathology</i> , 2012, 29, 12-18.	1.5	68
148	Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. <i>Blood</i> , 2011, 117, 3163-3171.	1.4	252
149	Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 4-10.	1.5	36
150	Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS. <i>Journal of Clinical Oncology</i> , 2010, 28, 3028-3034.	1.6	36
151	Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!. <i>Haematologica</i> , 2009, 94, 891-893.	3.5	44
152	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. <i>British Journal of Haematology</i> , 2009, 145, 624-636.	2.5	163
153	Clinical and biologic features of CD4+CD56+ malignancies. <i>Blood</i> , 2002, 99, 1556-1563.	1.4	404